Evidence map›Paper›PMID 25402179›Full record

ArticleComparative medicine2014

Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).

Lauren A Brush, Darla H Black, Kimberly A Mccormack, Lara K Maxwell, George Wright, Jerry W Ritchey, Mark E Payton, Richard Eberle

Abstract readComparative Study
PubMed Full text at PMC
In one paragraph

Article in Comparative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Understanding Primate Herpesviruses.Journal of emerging diseases and virology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lauren A BrushDepartment of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA.
Darla H BlackDepartment of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA.
Kimberly A MccormackDepartment of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA.
Lara K MaxwellDepartment of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma, USA.
George WrightDepartment of GLSynthesis, Worcester, Massachusetts, USA.
Jerry W RitcheyDepartment of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA.
Mark E PaytonDepartment of Department of Statistics, Oklahoma State University, Stillwater, Oklahoma, USA.
Richard EberleDepartment of Veterinary Pathobiology, Oklahoma State University, Stillwater, Oklahoma, USA. r.eberle@okstate.edu.
Oklahoma State University · US

Funding

Baboon Research Resource ProgramP40OD010988 · OD · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BANKS, RON E · 2012 to 2018
$9.0M
OUHSC Specific Pathogen Free Baboon Research ResourceP40OD010431 · OD · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BANKS, RON E, PAPIN, JAMES F · 2013 to 2017
$3.8M
Short Term Research Training for Veterinary StudentsT35OD011186 · OD · OKLAHOMA STATE UNIVERSITY STILLWATER · PI MALAYER, JERRY R · 2012 to 2014
$150k
NIH HHS P40 OD010431NIH HHS P40 OD010988NIH HHS T35 OD011186NIH HHS T38 OD011186
6 · The paper itself

Abstract

Monkey B virus (Macacine herpesvirus 1; BV) is endemic in macaques. BV (a BSL4 agent) is the primary zoonotic concern for persons working with macaques in research, and human BV infections frequently are fatal. We assessed the use of a BSL2 baboon herpesvirus (Papiine herpesvirus 1; HVP2) for predicting the drug sensitivity of BV by comparing the sensitivity of the 2 viruses to 12 antiherpetic drugs. Plaque reduction assays showed that 4 drugs (HBPG, BVdU, PFA, and BrdU) were ineffective against both viruses. Of the 8 effective drugs, both viruses were most sensitive to TFT, whereas sensitivity to the remaining 7 drugs varied between BV and HVP2 as well as between strains of HVP2. In addition, the efficacy of 5 drugs (ACV, PCV, GCV, CDV, and EDU) was tested by using a murine model. ACV and EDU were completely ineffective against both HVP2 and BV, and high doses of PCV only delayed death by a few days. GCV and CDV both protected mice against death, and CDV also prevented the development of neurologic symptoms. When the initiation of drug therapy was delayed until after virus gained access to the CNS, both GCV and CDV were ineffective. The similarity of the drug sensitivities of HVP2 and BV in both models validates the use of HVP2 as a BSL2 level model that can be used to predict drug sensitivity of BV. The greater efficacy of CDV relative to GCV suggests the potential for use of CDV in the treatment of zoonotic BV infections.

Indexed as

Disease Models, AnimalHerpesvirus 1, CercopithecineAnimalsAntiviral AgentsChlorocebus aethiopsCidofovirCytosineGanciclovirHerpesviridae InfectionsMacaca mulattaMiceOrganophosphonatesSimplexvirusTrifluridineVero CellsViral Plaque AssayAntiviral AgentsCidofovirCytosineGanciclovirOrganophosphonatesTrifluridine

Identifiers

PMID25402179
PMCPMC4236787
OpenAlexW2411259460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.